Stock Analysis

Don't Ignore The Insider Selling In PROCEPT BioRobotics

NasdaqGM:PRCT
Source: Shutterstock

Some PROCEPT BioRobotics Corporation (NASDAQ:PRCT) shareholders may be a little concerned to see that the President, Reza Zadno, recently sold a substantial US$976k worth of stock at a price of US$61.31 per share. That's a big disposal, and it decreased their holding size by 25%, which is notable but not too bad.

Check out our latest analysis for PROCEPT BioRobotics

Advertisement

The Last 12 Months Of Insider Transactions At PROCEPT BioRobotics

Over the last year, we can see that the biggest insider sale was by the Independent Director, Antal Desai, for US$9.0m worth of shares, at about US$97.59 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The silver lining is that this sell-down took place above the latest price (US$56.03). So it is hard to draw any strong conclusion from it.

In the last year PROCEPT BioRobotics insiders didn't buy any company stock. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
NasdaqGM:PRCT Insider Trading Volume March 14th 2025

I will like PROCEPT BioRobotics better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.

Does PROCEPT BioRobotics Boast High Insider Ownership?

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. PROCEPT BioRobotics insiders own about US$83m worth of shares. That equates to 2.6% of the company. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

So What Do The PROCEPT BioRobotics Insider Transactions Indicate?

Insiders sold PROCEPT BioRobotics shares recently, but they didn't buy any. And even if we look at the last year, we didn't see any purchases. Insider ownership isn't particularly high, so this analysis makes us cautious about the company. We'd practice some caution before buying! While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. You'd be interested to know, that we found 1 warning sign for PROCEPT BioRobotics and we suggest you have a look.

But note: PROCEPT BioRobotics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqGM:PRCT

PROCEPT BioRobotics

A surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally.

Flawless balance sheet with limited growth.

Advertisement